title: Particle and subunit-based hemagglutinin vaccines provide protective efficacy against H1N1 influenza in pigs.
abstract: The increasing diversity of influenza strains circulating in swine herds escalates the potential for the emergence of novel pandemic viruses and highlights the need for swift development of new vaccines. Baculovirus has proven to be a flexible platform for the generation of recombinant forms of hemagglutinin (HA) including subunit, VLP-displayed, and baculovirus-displayed antigens. These presentations have been shown to be efficacious in mouse, chicken, and ferret models but little is known about their immunogenicity in pigs. To assess the utility of these HA presentations in swine, Baculovirus constructs expressing HA fused to swine IgG2a Fc, displayed in a FeLV gag VLP, or displayed in the baculoviral envelope were generated. Vaccines formulated with these antigens wer The e administered to groups of pigs who were subsequently challenged with H1α cluster H1N1 swine influenza virus (SIV) A/Swine/Indiana/1726/88. Our results demonstrate that vaccination with any of these three vaccines elicits robust hemagglutinin inhibition titers in the serum and decreased the severity of SIV-associated lung lesions after challenge when compared to placebo-vaccinated controls. In addition, the number of pigs with virus detected in the lungs and nasal passages was reduced. Taken together, the results demonstrate that these recombinant approaches expressed with the baculovirus expression vector system may be viable options for development of SIV vaccines for swine.
authors.affiliation: Boehringer Ingelheim Vetmedica, Inc., Ames, IA 50010, United States. Electronic address: luis_1.hernandez@boehringer-ingelheim.com.
authors.forename: Luis A
authors.initials: LA
authors.lastname: Hernandez
authors.affiliation: Department of Veterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, United States.
authors.forename: Cathy L
authors.initials: CL
authors.lastname: Miller
authors.affiliation: Boehringer Ingelheim Vetmedica, Inc., Ames, IA 50010, United States.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Vaughn
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology*; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology / Q000592:standards*; D008168:Lung / Q000821:virology; D009666:Nose / Q000821:virology; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D011897:Random Allocation; D013552:Swine; D013553:Swine Diseases / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D022223:Vaccines, Subunit / Q000592:standards; D014614:Vaccines, Synthetic / Q000592:standards
chemical_list: D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic
keywords: Baculovirus; Hemagglutinin; Influenza; Subunit; Swine; VLP; Vaccine